Brain Glucose Hypometabolism and Brain Iron Accumulation as Therapeutic Targets for Alzheimer’s Disease and Other CNS Disorders
Open Access
- 19 February 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 271
Abstract
Two common mechanisms contributing to multiple neurological disorders, including Alzheimer’s disease, are brain glucose hypometabolism (BGHM) and brain iron accumulation (BIA). Currently, BGHM and BIA are both widely acknowledged as biomarkers that aid in diagnosing CNS disorders, distinguishing between disorders with similar symptoms, and tracking disease progression. Therapeutics targeting BGHM and BIA in Alzheimer’s disease can be beneficial in treating neurocognitive symptoms. This review addresses the evidence for the therapeutic potential of targeting BGHM and BIA in multiple CNS disorders. Intranasal insulin, which is anti-inflammatory and increases brain cell energy, and intranasal deferoxamine, which reduces oxidative damage and inflammation, represent promising treatments targeting these mechanisms. Both BGHM and BIA are promising therapeutic targets for AD and other CNS disorders.Keywords
This publication has 93 references indexed in Scilit:
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Association between iron accumulation in the dorsal striatum and compulsive drinking in alcohol use disorderPsychopharmacology, 2022
- MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trialJournal of Neurology, 2022
- Magnetic Resonance Iron Imaging in Amyotrophic Lateral SclerosisJournal of Magnetic Resonance Imaging, 2021
- Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non‐disease‐specific pathway of functional neurologic improvementBrain and Behavior, 2020
- Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson’s diseaseNeuroradiology, 2019
- Epilepsy and astrocyte energy metabolismGlia, 2017
- Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic miceExperimental Brain Research, 2012
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2012
- Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal gangliaAnnals of Neurology, 1992